Aytu Biopharma, Inc.
AYTU
$2.94
-$0.02-0.68%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 22.93M | 22.10M | 30.73M | 22.73M | 26.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.93M | 22.10M | 30.73M | 22.73M | 26.28M |
| Cost of Revenue | 6.73M | 7.32M | 12.17M | 9.99M | 8.99M |
| Gross Profit | 16.20M | 14.78M | 18.56M | 12.74M | 17.29M |
| SG&A Expenses | 12.02M | 14.38M | 14.10M | 19.98M | 18.58M |
| Depreciation & Amortization | 1.30M | 1.31M | 1.20M | 1.20M | 1.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.57M | 23.60M | 27.92M | 32.03M | 30.47M |
| Operating Income | 2.36M | -1.50M | 2.81M | -9.29M | -4.19M |
| Income Before Tax | 608.00K | -8.12M | -2.46M | -7.20M | -6.69M |
| Income Tax Expenses | 828.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -220.00K | -8.12M | -2.46M | -7.20M | -6.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.00K | -8.12M | -2.46M | -7.20M | -6.69M |
| EBIT | 2.36M | -1.50M | 2.81M | -9.29M | -4.19M |
| EBITDA | 4.54M | 726.00K | 4.93M | -7.10M | -1.99M |
| EPS Basic | -0.04 | -1.48 | -0.59 | -1.93 | -2.15 |
| Normalized Basic EPS | 0.07 | -0.98 | 0.03 | -1.33 | -0.81 |
| EPS Diluted | -0.04 | -1.48 | -0.60 | -1.93 | -2.15 |
| Normalized Diluted EPS | 0.07 | -0.98 | 0.03 | -1.33 | -0.81 |
| Average Basic Shares Outstanding | 5.52M | 5.48M | 4.14M | 3.73M | 3.11M |
| Average Diluted Shares Outstanding | 5.52M | 5.48M | 4.14M | 3.73M | 3.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
